Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Nora AI
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: XVIVO Q2 Update - Another roaring quarter

Xvivo Perfusion

XVIVO delivered an organic growth surprise at 32% (CER, 32% in Q1) during Q2 a quarter, with a substantial contribution from both the thoracic and abdominal business, whilst the OPEX level is contained. The outlook remains positive, and the critical US Heart study is underway. Our updated Base Case is SEK 575 (460) with a Bull Case of SEK 1,100 (925) and a Bear Case of SEK 165 (115).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


XVIVO Q2 Update - Another roaring quarter

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.